144 related articles for article (PubMed ID: 37995007)
1. Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis.
Hong Y; Miao Q; Zheng X; Xu Y; Huang Y; Chen S; Huang Z; Xu H; Jiang K; Zhong Q; Zhang L; Zheng X; Zeng H; Yang S; Li Y; Li S; Zhuang W; Lin G
J Neurooncol; 2023 Nov; 165(2):301-312. PubMed ID: 37995007
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.
Park JH; Kim YJ; Lee JO; Lee KW; Kim JH; Bang SM; Chung JH; Kim JS; Lee JS
Lung Cancer; 2012 Jun; 76(3):387-92. PubMed ID: 22186628
[TBL] [Abstract][Full Text] [Related]
3. Safety, Pharmacokinetic and Clinical Activity of Intrathecal Chemotherapy With Pemetrexed via the Ommaya Reservoir for Leptomeningeal Metastases From Lung Adenocarcinoma: A Prospective Phase I Study.
Li H; Zheng S; Lin Y; Yu T; Xie Y; Jiang C; Liu X; Qian X; Yin Z
Clin Lung Cancer; 2023 Mar; 24(2):e94-e104. PubMed ID: 36588048
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study.
Zhou T; Zhu S; Xiong Q; Gan J; Wei J; Cai J; Liu A
BMC Cancer; 2023 Apr; 23(1):333. PubMed ID: 37041504
[TBL] [Abstract][Full Text] [Related]
5. [Clinical trials on intrathecal pemetrexed treated leptomeningeal metastases from solid tumors].
Pan ZY; Song YY; Jiang TC; Yang X; Yang GZ
Zhonghua Zhong Liu Za Zhi; 2022 Jan; 44(1):112-119. PubMed ID: 35073657
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial.
Fan C; Jiang Z; Teng C; Song X; Li L; Shen W; Jiang Q; Huang D; Lv Y; Du L; Wang G; Hu Y; Man S; Zhang Z; Gao N; Wang F; Shi T; Xin T
ESMO Open; 2024 Apr; 9(4):102384. PubMed ID: 38377785
[TBL] [Abstract][Full Text] [Related]
7. A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer.
Geng D; Guo Q; Huang S; Zhang H; Guo S; Li X
Technol Cancer Res Treat; 2022; 21():15330338221078429. PubMed ID: 35289201
[No Abstract] [Full Text] [Related]
8. Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.
Riess JW; Nagpal S; Iv M; Zeineh M; Gubens MA; Ramchandran K; Neal JW; Wakelee HA
Clin Lung Cancer; 2014 May; 15(3):202-6. PubMed ID: 24524822
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.
Choi M; Keam B; Ock CY; Kim M; Kim TM; Kim DW; Heo DS
Clin Lung Cancer; 2019 Jul; 20(4):e442-e451. PubMed ID: 31010639
[TBL] [Abstract][Full Text] [Related]
10. Multiple combination therapy based on intrathecal pemetrexed in non-small cell lung cancer patients with refractory leptomeningeal metastasis.
Miao Q; Zheng X; Zhang L; Jiang K; Wu B; Lin G
Ann Palliat Med; 2020 Nov; 9(6):4233-4245. PubMed ID: 33302683
[TBL] [Abstract][Full Text] [Related]
11. Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor.
Kwon BS; Cho YH; Yoon SK; Lee DH; Kim SW; Kwon DH; Lee JC; Choi CM
Thorac Cancer; 2020 Feb; 11(2):436-442. PubMed ID: 31910497
[TBL] [Abstract][Full Text] [Related]
12. [Clinical characteristics and their influences on the survival of leptomeningeal metastasis derived from lung adenocarcinoma harboring epithelial growth factor receptor mutation].
Jiang AF; Zhou SS; Zhou Q; Zhao J; Li XP; Zhou RR; Li B
Zhonghua Yi Xue Za Zhi; 2023 Sep; 103(34):2713-2719. PubMed ID: 37675543
[No Abstract] [Full Text] [Related]
13. Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis.
Frost N; Zhamurashvili T; von Laffert M; Klauschen F; Ruwwe-Glösenkamp C; Raspe M; Brunn M; Ochsenreither S; Temmesfeld-Wollbrück B; Suttorp N; Grohé C; Witzenrath M
Clin Lung Cancer; 2020 Nov; 21(6):e607-e621. PubMed ID: 32620471
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of EGFR/ALK alterations in leptomeningeal metastasis from lung adenocarcinoma treated with whole-brain radiotherapy.
Oyoshi H; Hirata H; Hirano Y; Zenda S; Zhou Y; Tomizawa K; Fujisawa T; Nakamura M; Hojo H; Motegi A; Kageyama SI; Zenke Y; Goto K; Ishihara S; Naganawa S; Akimoto T
Clin Exp Metastasis; 2023 Oct; 40(5):407-413. PubMed ID: 37468822
[TBL] [Abstract][Full Text] [Related]
17. Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer.
Liu X; Li G; Zhang H; Chang Q; Fang M; Lu C; Tian P; Mei F
Clin Neurol Neurosurg; 2023 Feb; 225():107572. PubMed ID: 36610238
[TBL] [Abstract][Full Text] [Related]
18. Complete remission in leptomeningeal metastasis of NSCLC with rare EGFR-SEPT14 fusion treated with osimertinib combined with intrathecal chemotherapy with pemetrexed.
Zheng S; Li H; Feng J; Jiang C; Lin Y; Xie Y; Yu T; Qian X; Yin Z
Anticancer Drugs; 2022 Jan; 33(1):e795-e798. PubMed ID: 34486539
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.
Yang H; Yang X; Zhang Y; Liu X; Deng Q; Zhao M; Xu X; He J
Target Oncol; 2015 Mar; 10(1):135-40. PubMed ID: 24985049
[TBL] [Abstract][Full Text] [Related]
20. Outcomes, responses, and prognostic analyses of intrathecal combined treatment for leptomeningeal metastasis from lung adenocarcinoma.
Huang S; Kang X; Wang C; Zhang W; Jiang J; Kang Z; Yang S; Chen J; Chen F; Li W
J Cancer Res Ther; 2024 Apr; 20(2):658-664. PubMed ID: 38687937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
